Apolipoprotein A1 regulates coenzyme Q10 absorption, mitochondrial function, and infarct size in a mouse model of myocardial infarction

Journal of Nutrition

Volumn 144, Issue 7, 2014, Pages 1030-1036

  Dadabayev, Alisher R ^a   Yin, Guotian ^b,c   Latchoumycandane, Calivarathan ^a   McIntyre, Thomas M ^a   Lesnefsky, Edward J ^b   Penn, Marc S ^d,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c XINXIANG MEDICAL UNIVERSITY   (China)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^e SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CELL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ELECTRON TRANSPORT; GENE DOSAGE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REPERFUSION INJURY; RESPIRATORY CHAIN; TISSUE INJURY; WILD TYPE;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; CARDIOTONIC AGENTS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; HEART; HYPOALPHALIPOPROTEINEMIAS; INJECTIONS, INTRAPERITONEAL; INTESTINAL ABSORPTION; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; TISSUE DISTRIBUTION; UBIQUINONE;

EID: 84904671447     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.113.184291     Document Type: Article

References (51)

1. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 20000;86:19L-22L.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-14.
3. Baker HN, Delahunty T, Gotto AM Jr, Jackson RL. The primary structure of high density apolipoprotein-glutamine-I. Proc Natl Acad Sci USA. 1974;71:3631-4.
4. Delahunty T, Baker HN, Gotto AM Jr, Jackson RL. The primary structure of human plasma high density apolipoprotein glutamine I (ApoA-I). I. The amino acid sequence of cyanogen bromide fragment II. J Biol Chem. 1975;250:2718-24.
5. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, Yamakawa K, Yamanouchi Y, Tanaka I, Obara T, Hamaguchi H. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci USA. 1991;88:2793-7.
6. Williamson R, Lee D, Hagaman J, Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci USA. 1992;89:7134-8.
7. Karathanasis SK, Zannis VI, Breslow JL. A DNA insertion in the apolipoprotein A-I gene of patients with premature atherosclerosis. Nature. 1983;305:823-5.
8. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueck CJ, Vergani C, Wilson PW, Karathanasis SK. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med. 1986;314:671-7.
9. Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med. 2006;6:571-87.
10. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005;25:1325-31.
11. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, Roux-Lombard P, Burger D. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood. 2001;97:2381-9.
12. Jiao YL, Wu MP. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine. 2008;43:83-7.
13. MarchesiM, Booth EA, Davis T, Bisgaier CL, Lucchesi BR. Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemiareperfusion injury. J Pharmacol Exp Ther. 2004;311:1023-31.
14. Marchesi M, Booth EA, Rossoni G, Garcia RA, Hill KR, Sirtori CR, Bisgaier CL, Lucchesi BR. Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis. 2008;197:572-8.
15. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JT, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615-24.
16. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am Heart J. 1986;112:682-90.
17. Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, Spitz DR, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation. 2005;112:2812-20.
18. Carrea FP, Lesnefsky EJ, Repine JE, Shikes RH, Horwitz LD. Reduction of canine myocardial infarct size by a diffusible reactive oxygen metabolite scavenger. Efficacy of dimethylthiourea given at the onset of reperfusion. Circ Res. 1991;68:1652-9.
19. Chen Q, Camara AK, Stowe DF, Hoppel CL, Lesnefsky EJ. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion. Am J Physiol Cell Physiol. 2007;292:C137-47.
20. Zuo L, Chen YR, Reyes LA, Lee HL, Chen CL, Villamena FA, Zweier JL. The radical trap 5,5-dimethyl-1-pyrroline N-oxide exerts dosedependent protection against myocardial ischemia-reperfusion injury through preservation of mitochondrial electron transport. J Pharmacol Exp Ther. 2009;329:515-23.
21. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther. 2012;26:227-37.
22. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118:1768-75.
23. Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K, Chen SF, Hoffman EK, Scott RW, Epstein CJ, Chan PH. Reduction of CuZnsuperoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci. 1997;17:4180-9.
24. Murakami K, Kondo T, Kawase M, Li Y, Sato S, Chen SF, Chan PH. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci. 1998;18:205-13.
25. Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol. 2004;55:668-75.
26. Rothe G, Valet G. Flow cytometric assays of oxidative burst activity in phagocytes. Methods Enzymol. 1994;233:539-48.
27. Hoppel CL, Kerr DS, Dahms B, Roessmann U. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex I of mitochondrial electron transport. Fatal infantile lactic acidosis and hypermetabolism with skeletal-cardiac myopathy and encephalopathy. J Clin Invest. 1987;80:71-7.
28. Lesnefsky EJ, Tandler B, Ye J, Slabe TJ, Turkaly J, Hoppel CL. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria. Am J Physiol. 1997;273:H1544-54.
29. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem. 2003;278:36027-31.
30. Boitier E, Degoul F, Desguerre I, Charpentier C, Francois D, Ponsot G, Diry M, Rustin P, Marsac C. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci. 1998;156:41-6.
31. Plump AS, Azrolan N, Odaka H, Wu L, Jiang X, Tall A, Eisenberg S, Breslow JL. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res. 1997;38:1033-47.
32. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977;55:767-72.
33. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980;46:649-54.
34. Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE, Ohman EM, Smith SC, Jr., Peterson ED. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2008;29:2480-8.
35. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation. 1991;84:129-39.
36. Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors. 2008;32:119-28.
37. Xia S, Xu S, Zhang X, Zhong F, Wang Z. Nanoliposomes mediate coenzyme Q10 transport and accumulation across human intestinal Caco-2 cell monolayer. J Agric Food Chem. 2009;57:7989-96.
38. Kayser EB, Sedensky MM, Morgan PG, Hoppel CL. Mitochondrial oxidative phosphorylation is defective in the long-lived mutant clk-1. J Biol Chem. 2004;279:54479-86.
39. Jonassen T, Larsen PL, Clarke CF. A dietary source of coenzyme Q is essential for growth of long-lived Caenorhabditis elegans clk-1 mutants. Proc Natl Acad Sci USA. 2001;98:421-6.
40. Kayser EB, Morgan PG, Sedensky MM.Mitochondrial complex I function affects halothane sensitivity in Caenorhabditis elegans. Anesthesiology. 2004;101:365-72.
41. Jonassen T, Marbois BN, Faull KF, Clarke CF, Larsen PL. Development and fertility in Caenorhabditis elegans clk-1 mutants depend upon transport of dietary coenzyme Q8 to mitochondria. J Biol Chem. 2002;277:45020-7.
42. Chen Q, Yin G, Stewart S, Hu Y, Lesnefsky EJ. Isolating the segment of the mitochondrial electron transport chain responsible for mitochondrial damage during cardiac ischemia. Biochem Biophys Res Commun. 2010;397:656-60.
43. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992;1126:247-54.
44. Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol. 1986;24:536-41.
45. Correia LC, Rocha MS, Esteves JP. HDL-cholesterol level provides additional prognosis in acute coronary syndromes. Int J Cardiol. 2009;136:307-14.
46. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10:453-64.
47. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
48. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007;195:e182-9.
49. Päivä H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimä ki T, von Bergmann K, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60-8.
50. Landi F, Russo A, Cesari M, Pahor M, Bernabei R, Onder G. HDLcholesterol and physical performance: results from the ageing and longevity study in the sirente geographic area (ilSIRENTE Study). Age Ageing. 2007;36:514-20.
51. Iwaoka M, Obata JE, Abe M, Nakamura T, Kitta Y, Kodama Y, Kawabata K, Takano H, Fujioka D, Saito Y, et al. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail. 2007;13:247-53.